Evaxion Biotech News and Activities

Evaxion Biotech is a company listed under the stock ticker EVAX (DK).

View the org chart displaying its 14 main executives

Most searched biographies at Evaxion Biotech

• Helen Tayton-Martin, Chief Executive Officer
• Jens Norhave, Director
• Marianne Søgaard, Chairman of the Board

Popular executive movements at Evaxion Biotech

• Birgitte Rønø, who was Chief Scientific Officer, is promoted to Chief Science and Chief Operating Officer  (posted on April 27 2026).
• Helen Tayton-Martin who is Director, will be promoted to Chief Executive Officer on Nov. 24, 2025  (posted on October 28 2025).
• Birgitte Rønø who was Interim Chief Executive Officer and Chief Scientific Officer, becomes Chief Scientific Officer  (posted on October 27 2025).

Create your alert
to follow the executive moves at Evaxion Biotech.

Evaxion Biotech has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Evaxion Biotech

• Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials | Evaxion Biotech
• Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform | Evaxion Biotech
• Evaxion significantly expands vaccine development collaboration with MSD | Evaxion Biotech
• Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction | Evaxion Biotech
• Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 | Evaxion Biotech
• Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 | Evaxion Biotech
• Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 | Evaxion Biotech
• Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September | Evaxion Biotech
• Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 | Evaxion Biotech
• Evaxion Announces Business Update and Second Quarter 2024 Financial Results | Evaxion Biotech
• View more press releases Close

Social media about Evaxion Biotech

• Evaxion Biotech on Wikipedia, Google News & Yahoo Finance
• Evaxion Biotech on LinkedIn, X (Twitter) & YouTube